Elisabeth Weiss1, Xiaoyan Deng2, Nitai Mukhopadhyay2, Nuzhat Jan1. 1. Department of Radiation Oncology, Virginia Commonwealth University Health, Richmond, VA, USA. 2. Department of Biostatistics, Virginia Commonwealth University Health, Richmond, VA, USA.
Abstract
Background: Information on the effect of the recurrence pattern on survival for stage I lung cancer following stereotactic ablative radiotherapy (SABR) is limited.Materials and Methods: The recurrence pattern was analyzed for 100 consecutive stage I non-small-cell lung cancer patients treated with SABR using predominantly 12 Gy × 4. Recurrences were classified as local, regional lymph nodes and distant. Distant recurrences included recurrences in the lung and outside the chest. Single lung recurrences were named solitary, if no other location was involved. Kaplan-Meier survival estimates were calculated for different locations of recurrence. Clinical and dosimetrical factors affecting survival were also analyzed. Results: Median follow-up was 32 months (3-123), median age 70 years (49-95). In total, 31 patients had recurrences after a median 21 months (4-60): 5 local; 10 regional; 8 distant outside the chest; 25 non-local lung recurrences, of which 15 were single - 10 of which solitary - and 10 multiple lung nodules. Patients with a solitary lung recurrence had longer survival compared to local or distant recurrences (p = .04 each), and compared to multiple lung nodules (p = .09). 3-year local recurrence-free survival was 92%, disease-free survival 69% and overall survival 59%. On multivariate analysis, disease-free survival was associated with statin use (p = .038) and tumor location (p = .035). Smoking history predicted overall survival (p < .0006).Conclusions: A total of 81% of recurrences involved the lungs. Patients with solitary lung recurrences/second primary lung cancers had the longest overall survival suggesting definitive treatment should be considered. The effects of statin use need to be explored further.
Background: Information on the effect of the recurrence pattern on survival for stage I lung cancer following stereotactic ablative radiotherapy (SABR) is limited.Materials and Methods: The recurrence pattern was analyzed for 100 consecutive stage I non-small-cell lung cancerpatients treated with SABR using predominantly 12 Gy × 4. Recurrences were classified as local, regional lymph nodes and distant. Distant recurrences included recurrences in the lung and outside the chest. Single lung recurrences were named solitary, if no other location was involved. Kaplan-Meier survival estimates were calculated for different locations of recurrence. Clinical and dosimetrical factors affecting survival were also analyzed. Results: Median follow-up was 32 months (3-123), median age 70 years (49-95). In total, 31 patients had recurrences after a median 21 months (4-60): 5 local; 10 regional; 8 distant outside the chest; 25 non-local lung recurrences, of which 15 were single - 10 of which solitary - and 10 multiple lung nodules. Patients with a solitary lung recurrence had longer survival compared to local or distant recurrences (p = .04 each), and compared to multiple lung nodules (p = .09). 3-year local recurrence-free survival was 92%, disease-free survival 69% and overall survival 59%. On multivariate analysis, disease-free survival was associated with statin use (p = .038) and tumor location (p = .035). Smoking history predicted overall survival (p < .0006).Conclusions: A total of 81% of recurrences involved the lungs. Patients with solitary lung recurrences/second primary lung cancers had the longest overall survival suggesting definitive treatment should be considered. The effects of statin use need to be explored further.
Authors: Sameer K Nath; Ajay P Sandhu; Daniel Kim; Anjali Bharne; Polly D Nobiensky; Joshua D Lawson; Mark Fuster; Lyudmila Bazhenova; William Y Song; Arno J Mundt Journal: Radiother Oncol Date: 2011-03-21 Impact factor: 6.280
Authors: Inga Siiner Grills; Andrew J Hope; Matthias Guckenberger; Larry L Kestin; Maria Werner-Wasik; Di Yan; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Juergen Wilbert; Ying Xiao; Jose Belderbos Journal: J Thorac Oncol Date: 2012-09 Impact factor: 15.609
Authors: Kevin L Stephans; Neil M Woody; Chandana A Reddy; Matthew Varley; Anthony Magnelli; Tingliang Zhuang; Peng Qi; Gregory M M Videtic Journal: Int J Radiat Oncol Biol Phys Date: 2017-10-28 Impact factor: 7.038
Authors: Zishan Allibhai; Mojgan Taremi; Andrea Bezjak; Anthony Brade; Andrew J Hope; Alexander Sun; B C John Cho Journal: Int J Radiat Oncol Biol Phys Date: 2013-10-24 Impact factor: 7.038
Authors: Carol H Christensen; Brian Rostron; Candace Cosgrove; Sean F Altekruse; Anne M Hartman; James T Gibson; Benjamin Apelberg; Maki Inoue-Choi; Neal D Freedman Journal: JAMA Intern Med Date: 2018-04-01 Impact factor: 21.873
Authors: Xiaoli Zheng; Yanan Sun; Ke Ye; Chengcheng Fan; Xiaohui Wang; Yang Yang; Ruidi Jiao; Hong Ge Journal: Thorac Cancer Date: 2021-02-02 Impact factor: 3.500